We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Line of Immunoassay Stabilizers Launched at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
The launch and immediate availability of a new line of advanced immunoassay stabilizers were announced prior to the commencement of the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Surmodics (Eden Prairie, MN, USA) StabilBlock Immunoassay Stabilizer, which will be on display in Booth 4047 of the expo, is advertised as the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.

Surmodics offers a family of immunoassay stabilizers, which preserve the conformation and activity of dried proteins on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity. With StabilCoat, StabilGuard, and the new StabilBlock immunoassay stabilizers, the company now offers three options to assay developers with a combination of blocking efficacy and long-term dried stability that is unmatched in the industry.

“As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers,” said Joe Stich, vice- president and general manager of Surmodics IVD. “We recognize that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilizers will enable assay developers to achieve the best results for each application.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Surmodics



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.